These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11929643)

  • 1. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables.
    Endrikat J; Klipping C; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2002 Mar; 65(3):215-21. PubMed ID: 11929643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel.
    Jespersen J; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Sidelmann JJ; Skouby SO
    Contraception; 2005 Aug; 72(2):98-104. PubMed ID: 16022847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism.
    Endrikat J; Klipping C; Gerlinger C; Ruebig A; Schmidt W; Holler T; Düsterberg B
    Contraception; 2001 Oct; 64(4):235-41. PubMed ID: 11747873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.
    Junge W; Heger-Mahn D; Trummer D; Merz M
    Drugs R D; 2013 Sep; 13(3):223-33. PubMed ID: 24043457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone.
    Endrikat J; Hite R; Bannemerschult R; Gerlinger C; Schmidt W
    Contraception; 2001 Jul; 64(1):3-10. PubMed ID: 11535206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four month clinical trial.
    Young RL; DelConte A
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):59-62. PubMed ID: 10561677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
    Skouby SO; Wagner HH; Andersen O
    Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors.
    Archer DF; Mammen EF; Grubb GS
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):63-6. PubMed ID: 10561678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.
    Junge W; Mellinger U; Parke S; Serrani M
    Clin Drug Investig; 2011; 31(8):573-584. PubMed ID: 21721593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study.
    Magnusdóttir EM; Bjarnadóttir RI; Onundarson PT; Gudmundsdóttir BR; Geirsson RT; Magnusdóttir SD; Dieben TO
    Contraception; 2004 Jun; 69(6):461-7. PubMed ID: 15157790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size.
    Foulon T; Payen N; Laporte F; Bijaoui S; Dupont G; Roland F; Groslambert P
    Contraception; 2001 Jul; 64(1):11-6. PubMed ID: 11535207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.
    van der Mooren MJ; Klipping C; van Aken B; Helmerhorst E; Spielmann D; Kluft C
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():27-35. PubMed ID: 14677622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol.
    Reisman H; Martin D; Gast MJ
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):45-52. PubMed ID: 10561675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.